Therapeutic resistance in prostate cancer can be driven by lineage plasticity, but the mechanisms behind this are unclear, and therapies to prevent or reverse the process are nonexistent. A new study reveals the JAK/STAT signaling axis as a driver of lineage plasticity with tremendous therapeutic potential.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bluemn, E. G. et al. Cancer Cell 32, 474–489 e6 (2017).
Beltran, H. et al. Nat. Med. 22, 298–305 (2016).
Beltran, H. et al. J. Clin. Invest. 130, 1653–1668 (2020).
Berger, A. et al. 129, 3924-3940 (2019).
Augello, M. A. et al. Cancer Cell 35, 603–617 e8 (2019).
Zhang, Z. et al. Cancer Cell 37, 584–598 e11 (2020).
Ku, S. Y. et al. Science 355, 78–83 (2017).
Brady, N. J. et al. Nat. Commun. 12, 3372 (2021).
Lee, J. K. et al. Cancer Cell 29, 536–547 (2016).
Dardenne, E. et al. Cancer Cell 30, 563–577 (2016).
Bishop, J. L. et al. Cancer Discov. 7, 54–71 (2017).
Mu, P. et al. Science 355, 84–88 (2017).
Deng, S. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00431-9 (2022).
Tang, F. et al. Science 376, eabe1505 (2022).
Irey, E. A. et al. Proc. Natl Acad. Sci. USA 116, 12442–12451 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Brady, N.J., Barbieri, C.E. JAK inhibition shows two faces in prostate cancer. Nat Cancer 3, 1021–1023 (2022). https://doi.org/10.1038/s43018-022-00437-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00437-3